Background Evidence from diabetic animal models suggests that cilostazol, a cyclic AMP phosphodiesterase inhibitor used in the treatment of claudication, is efficacious in the treatment of peripheral neuropathy, although this is unproven in humans. The main aim of this study was to assess the effects of cilostazol on neuropathic symptomatology in diabetic patients with peripheral arterial disease (PAD). Methods Diabetic patients with PAD were prospectively recruited to a randomized double-blinded placebo-controlled trial. Baseline clinical data were recorded prior to trial commencement following medical optimization. Neurological assessment included the Toronto Clinical Neuropathy Scoring system (TCNS) and vibration perception thresholds (VPT) with a neurothesiometer at baseline, 6 weeks, and 24 weeks. Results Twenty-six patients were recruited from December 2004 to January 2006, which included 20 males. Baseline patient allocation to treatment arms was matched for age, sex, and medical comorbidities. There was no significant difference in neurological assessment between the treatment groups using the TCNS and VPT at 6 and 24 weeks. Conclusions Despite extensive animal-based evidence that cilostazol attenuates neuropathic symptomatology, our results do not support this effect in human diabetic PAD patients.
Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AWAssessment and management of foot disease in patients with diabetes . New Engl J Med. 1994;331:854-860.
2.
Holzer SE, Camerota A., Martens L., Cuerdon T., Crystal-Peters J., Zagari M.Costs and duration of care for lower extremity ulcers in patients with diabetes . Clin Ther. 1998;20:169-181.
3.
Vinik A., Mitchell B., Leichter S., Wagner A., O'Brian J., Georges L.Epidemiology of the Complications of Diabetes. Cambridge , UK: Cambridge University Press; 1995:221-287.
4.
Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PHA multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia . 1993;36: 150-154.
5.
Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817-824.
6.
Boulton AJLowering the risk of neuropathy, foot ulcers and amputations. Diabet Med. 1998;15(suppl 4):S57-S59.
7.
Boulton AJThe diabetic foot: a global view. Diabetes Metab Res Rev. 2000;16(suppl 1):S2-S5.
8.
Ward JDImproving prognosis in type 2 diabetes. Diabetic neuropathy is in trouble . Diabetes Care. 1999;22(suppl 2):B84-B88.
9.
Greene DA, Lattimer SA, Sima AASorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. New Engl J Med. 1987;316:599-606.
10.
Tesfaye S., Malik R., Ward JDVascular factors in diabetic neuropathy. Diabetologia. 1994;37:847-854.
11.
Lattimer SA , Sima AA, Greene DAIn vitro correction of impaired Na+-K+-ATPase in diabetic nerve by protein kinase C agonists. Am J Physiol . 1989;256(2, pt 1): E264-E269.
12.
Dyck PJ, Hansen S., Karnes J., et al. Capillary number and percentage closed in human diabetic sural nerve. Proc Natl Acad Sci U S A. 1985;82:2513-2517.
13.
Giannini C. , Dyck PJBasement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity. Ann. Neurol.1995;37:498-504.
14.
Malik RA, Veves A., Masson EA, et al. Endoneurial capillary abnormalities in mild human diabetic neuropathy . J Neurol Neurosurg Psychiatry. 1992;55:557-561.
15.
Malik RA, Newrick PG, Sharma AK, et al. Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy. Diabetologia . 1989;32:92-102.
16.
Giannini C., Dyck PJUltrastructural morphometric abnormalities of sural nerve endoneurial microvessels in diabetes mellitus. Ann Neurol. 1994;36:408-415.
17.
Bradley J., Thomas PK, King RH, Llewelyn JG, Muddle JR, Watkins PJMorphometry of endoneurial capillaries in diabetic sensory and autonomic neuropathy . Diabetologia. 1990;33:611-618.
18.
Britland ST, Young RJ, Sharma AK, Clarke BFRelationship of endoneurial capillary abnormalities to type and severity of diabetic polyneuropathy. Diabetes. 1990 ;39:909-913.
19.
Sima AA, Nathaniel V., Prashar A., Bril V., Greene DAEndoneurial microvessels in human diabetic neuropathy. Endothelial cell dysjunction and lack of treatment effect by aldose reductase inhibitor . Diabetes.1991;40: 1090-1099.
20.
Okuda Y., Mizutani M., Ikegami T., Ueno E., Yamashita K.Hemodynamic effects of cilostazol on peripheral artery in patients with diabetic neuropathy. Arzneimittelforschung. 1992;42:540-542.
21.
Boulton AJ, Vileikyte L., Ragnarson-Tennvall G., Apelqvist J.The global burden of diabetic foot disease. Lancet . 2005;366:1719-1724.
22.
Bartus CL, Margolis DJReducing the incidence of foot ulceration and amputation in diabetes . Curr Diab Rep. 2004;4:413-418.
Chapman TM, Goa KLCilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs. 2003;3:117-138.
25.
Liu Y., Shakur Y., Yoshitake M., Kambayashi J.Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev. 2001;19:369-386.
26.
Reilly MP, Mohler ER, III.Cilostazol: treatment of intermittent claudication. Ann Pharmacother . 2001;35 :48-56.
27.
Sun B., Le SN, Lin S., et al. New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation. J Cardiovasc Pharmacol. 2002;40:577-585.
28.
Wang S., Cone J., Fong M., Yoshitake M., Kambayashi J., Liu Y.Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication . J Cardiovasc Pharmacol. 2001;38:775-783.
29.
Yamamoto Y. , Yasuda Y., Kimura Y., Komiya Y.Effects of cilostazol, an antiplatelet agent, on axonal regeneration following nerve injury in diabetic rats. Eur J Pharmacol. 1998;352:171-178.
30.
Myall OT, Allen SL, McLean WGThe effect of acrylamide on the induction of ornithine decarboxylase in the dorsal root ganglion of the rat. Brain Res. 1990;523:295-297.
31.
Cameron NE, Cotter MA, Dines KC, Maxfield EK, Carey F., Mirrlees DJAldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism. Diabetologia. 1994;37:651-663.
32.
Suh KS, Oh SJ, Woo JT, et al. Effect of cilostazol on the neuropathies of streptozotocin-induced diabetic rats. Korean J Intern Med. 1999;14:34-40.
33.
Naka K., Sasaki H., Kishi Y., et al. Effects of cilostazol on development of experimental diabetic neuropathy: functional and structural studies, and Na+-K+-ATPase acidity in peripheral nerve in rats with streptozotocin-induced diabetes. Diabetes Res Clin Pract. 1995;30:153-162.
34.
Uehara K., Sugimoto K., Wada R., et al. Effects of cilostazol on the peripheral nerve function and structure in STZ-induced diabetic rats. J Diabetes Complications. 1997;11:194-202.
35.
Kihara M., Schmelzer JD, Low PAEffect of cilostazol on experimental diabetic neuropathy in the rat . Diabetologia. 1995;38:914-918.
36.
Norgren L., Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(suppl 1):S1-S75.
37.
Alberti Kgmm , Aschner P., Assal J-P., et al. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation-Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, Switzerland: World Health Organization; 1999 .
Mallikaarjun S., Forbes WP, Bramer SLInteraction potential and tolerability of the coadministration of cilostazol and aspirin. Clin Pharmacokinet . 1999;37 (suppl 2):87-93.
40.
Mallikaarjun S., Bramer SLEffect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin. Clin Pharmacokinet. 1999;37(suppl 2):79-86.
41.
Bril V., Perkins BAValidation of the Toronto Clinical Scoring System for diabetic polyneuropathy . Diabetes Care. 2002;25:2048-2052.
42.
Goldberg M. , Lindblom U.Standardised method of determining vibratory perception thresholds for diagnosis and screening in neurological investigation . J Neurol Neurosurg Psychiatry. 1979;42:793-803.
43.
Kimura M.Effects of Pletal on incidence of sensory dysfunctions in diabetics . J New Remedies Clin. 1996;45: 371-376.
44.
Takei I., Nakamoto S., Ishii M., et al. Cilostazol, a phosphodiesterase inhibitor for the treatment of diabetic neuropathy. Diabetes Res. 1997 ;32:19-25.
45.
Sekiguchi M. , Morikawa A., Nakajima K., et al. Clinical usefulness of cilostazol (Pletal) on diabetic neuropathy and serum lipids levels. Jpn Pharmacol Ther. 1991;19:3273-3277.
46.
Rosenstock J. , Tuchman M., LaMoreaux L., Sharma U.Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628-638.
47.
Hiatt W.The US experience with cilostazol in treating intermittent claudication . Atherosclerosis. 2006;6:21-31.
48.
Pratt CMAnalysis of the cilostazol safety database. Am J Cardiol.2001;87:28D-33D.
49.
Thompson PD, Zimet R., Forbes WP, Zhang P.Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication . Am J Cardiol. 2002;90:1314-1319.
50.
Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med . 1999;159:2041-2050.
51.
Strandness DE Jr, Dalman RL, Panian S., et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovascular Surg. 2002;36:83-91.
52.
Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998;27:267-274.
53.
Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523-530.
54.
Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr.Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98:678-686.
